Success Metrics

Clinical Success Rate
100.0%

Based on 14 completed trials

Completion Rate
100%(14/14)
Active Trials
0(0%)
Results Posted
71%(10 trials)

Phase Distribution

Ph phase_1
2
13%
Ph phase_3
7
47%
Ph phase_4
1
7%
Ph not_applicable
1
7%
Ph phase_2
3
20%

Phase Distribution

2

Early Stage

3

Mid Stage

8

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
2(14.3%)
Phase 2Efficacy & side effects
3(21.4%)
Phase 3Large-scale testing
7(50.0%)
Phase 4Post-market surveillance
1(7.1%)
N/ANon-phased studies
1(7.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.3%

14 of 15 finished

Non-Completion Rate

6.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

15

all time

Status Distribution
Completed(14)
Terminated(1)

Detailed Status

Completed14
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (14.3%)
Phase 23 (21.4%)
Phase 37 (50.0%)
Phase 41 (7.1%)
N/A1 (7.1%)

Trials by Status

completed1493%
withdrawn17%

Recent Activity

0 active trials
Showing 5 of 15
completedphase_2

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02175342
completed

Re-usable Respimat® Soft MistTM Inhaler Study

NCT04011735
completednot_applicable

Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD Patients

NCT02331940
completedphase_4

Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge

NCT02622243
completedphase_3

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients

NCT01533922
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT02175342Phase 2

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT04011735

Re-usable Respimat® Soft MistTM Inhaler Study

Completed
NCT02331940Not Applicable

Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD Patients

Completed
NCT02622243Phase 4

Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge

Completed
NCT01533922Phase 3

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients

Completed
NCT01533935Phase 3

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.

Completed
NCT01431274Phase 3

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT01559116Phase 3

Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease

Completed
NCT01431287Phase 3

Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT01040403Phase 2

Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT01536262Phase 3

Japan Long-term Safety for Tiotropium Plus Olodaterol

Completed
NCT02254720Phase 1

Safety, Tolerability and Pharmacokinetics of BEA 2180 BR in Healthy Male Volunteers

Completed
NCT02254122Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BEA 2180 BR in Healthy Male Volunteers

Completed
NCT00387088Phase 3

Tiotropium / Respimat One Year Study in COPD.

Completed
NCT01428622Phase 2

Olodaterol Bridging Study in Asthma

Withdrawn

All 15 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
15